Majority of survey respondents call for new
treatments to help manage phosphorus levels
WALTHAM,
Mass. and NEW YORK,
Nov. 4,
2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX) in
partnership with the National Kidney Foundation (NKF), today
announced results from a survey of patients with chronic kidney
disease (CKD) on dialysis conducted to better understand patients'
experience managing serum phosphorus levels. The survey found that
more than 80% of respondents struggle to manage their serum
phosphorus levels, with more than 90% citing a need for new
treatment options.
"Despite best efforts with current treatment strategies, a
significant proportion of patients have persistent
hyperphosphatemia, placing them at an increased risk for mineral
and bone disorder complications, including vascular disease," said
Joseph Vassalotti, MD, chief medical
officer for the National Kidney Foundation. "These survey results
point to the difficulty people living with kidney diseases treated
with dialysis have coping with low phosphorus diet and current
medication schedules."
"We are proud to bring the patient voice to this important
conversation," said Laura A.
Williams, MD, chief medical officer of Ardelyx. "The idea
for this survey, born from the Ardelyx Patient Advisory Council,
provides great insight into the challenges patients face managing
hyperphosphatemia and supports the need for innovation in this
space. As a company committed to putting patients first, and as a
CKD patient myself, we are proud of this collaborative effort that
truly captures the voice of patients with kidney disease on
dialysis."
Hyperphosphatemia is a serious condition resulting in an
abnormally elevated level of phosphorus in the blood that is
estimated to affect more than 745,000 dialysis patients in major
developed countries. Currently, dialysis patients are often
prescribed phosphate binders, the only class of medicine currently
available to treat hyperphosphatemia and control elevated serum
phosphorus levels, which require very frequent dosing of several
large pills multiple times per day with meals.
Survey findings reveal the daily burden dialysis patients face
as they, in partnership with their physicians, try to control their
serum phosphorus levels, including:
- Only 18% of patients reported consistently maintaining their
phosphorus within range on a monthly basis
- 89% found that it takes effort to manage their phosphorus, with
86% reporting at least some difficulty following a low phosphorus
diet
- 88% reported at least some difficulty taking phosphate binders,
with 60% reporting side effects from their phosphate binder pills,
including nausea, diarrhea, constipation, and vomiting.
- 92% noted a need for a better way to manage their phosphorus
levels
The survey, a collaborative effort, was conducted by the
National Kidney Foundation and sponsored by the Ardelyx, Inc.,
Patient Advisory Council, was conducted online between September 28, 2022 – October 8, 2022, evaluating 475 dialysis patients
who are currently prescribed phosphate binders and take an average
of seven binders per day participated in the survey.
Full results of the survey will be presented during an upcoming
webinar. Please visit paracellularpathway.com for additional
information on hyperphosphatemia.
About National Kidney
Foundation
The National Kidney Foundation (NKF) is the largest, most
comprehensive, and longstanding patient-centric organization
dedicated to the awareness, prevention, and treatment of kidney
disease in the U.S. For more information about NKF, visit
www.kidney.org.
About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and
commercialize innovative first-in-class medicines that meet
significant unmet medical needs. Ardelyx's first approved product,
IBSRELA® (tenapanor) is available in the
United States and Canada.
Ardelyx is developing XPHOZAH® (tenapanor), a novel product
candidate to control serum phosphorus in adult patients with CKD on
dialysis, which has completed three successful Phase 3 trials.
Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the
potential treatment of elevated serum potassium, or hyperkalemia, a
problem among certain patients with kidney and/or heart disease and
an early-stage program in metabolic acidosis, a serious electrolyte
disorder in patients with CKD. Ardelyx has established agreements
with Kyowa Kirin in Japan, Fosun
Pharma in China and Knight
Therapeutics in Canada for the
development and commercialization of tenapanor in their respective
territories.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/national-kidney-foundation-and-ardelyx-inc-survey-finds-dialysis-patients-struggle-to-maintain-serum-phosphorus-levels-301669219.html
SOURCE Ardelyx